AXIM Biotechnologies
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
6191 Cornerstone Ct E Ste 114, San Diego...Phone Number
(858) 923-4422Website
www.aximbiotech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About AXIM Biotechnologies
AXIM Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM's COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis.Explore more
AXIM Biotechnologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AXIM Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if AXIM Biotechnologies is spiking on competitors!
Check if AXIM Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
Click to see if AXIM Biotechnologies had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once AXIM Biotechnologies has new funding data
Congratulate Masked Content for being promoted to Masked Content at AXIM Biotechnologies
AXIM Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on AXIM Biotechnologies recently announced quarterly report
Product Launch: Get notified when AXIM Biotechnologies launches new products
Recommended Actions
Reach out to Masked Content who joined AXIM Biotechnologies as Masked Content
Find 2 more new buyers
Compare Similar Companies to AXIM Biotechnologies
Compare insights from companies similar to AXIM Biotechnologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AXIM Biotechnologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AXIM Biotechnologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AXIM Biotechnologies.
AXIM Biotechnologies Tech Stack
A closer look at the technologies used by AXIM Biotechnologies
Most Recent Scoops
New Hire
Executive Move
Promotion
Executive Move
Executive Move
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
AXIM Biotechnologies News & Media
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
SAN DIEGO--(BUSINESS WIRE)--AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the receipt of notification by the United States Patent & Trademark Office of several patent allowances. AXIM has been developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including, for example, SARS-Cov-2, Lactoferrin, IgE, Lacritin, MMP-9. This innVerséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform
TAMPA, Fla.--(BUSINESS WIRE)-- #DED--Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value diagnostic and therapeutic solutions to improve ocular disease, proudly announces the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow Readers. The company focuses on delivering innovative Tear-based Point-of-Care (T-POC) testing and biologic solutions that optimize diagnosis, treatment, and management of various eye careAXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay PlatformAXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
Leading Dry Eye Disease Diagnostic Healthcare Company’s Assays to be Performed in Over 40 Initial Clinics Across US
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AXIM Biotechnologies
Sign Up For FreeTo access detailed company insights
AXIM Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM's COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS... Read More
